Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Nicotine Patch Introduction Boosts First Quarter Sales Growth

This article was originally published in The Tan Sheet

Executive Summary

The introduction of Perrigo's private label nicotine transdermal system helped the firm post strong sales and earnings growth for the first quarter ended Oct. 2, the company announced Nov. 9.

You may also be interested in...



Perrigo chewses smoking cessation

Perrigo receives ANDA generic drug approvals for over-the-counter nicotine polacrilex gum in 2mg and 4 mg doses Sept. 16. The approvals total six, with regular, mint and orange flavors for each dose. The approvals build on the firm's existing smoking cessation portfolio of nicotine replacement patch products (1"The Tan Sheet" Nov. 15, 1999, p. 13)....

Perrigo chewses smoking cessation

Perrigo receives ANDA generic drug approvals for over-the-counter nicotine polacrilex gum in 2mg and 4 mg doses Sept. 16. The approvals total six, with regular, mint and orange flavors for each dose. The approvals build on the firm's existing smoking cessation portfolio of nicotine replacement patch products (1"The Tan Sheet" Nov. 15, 1999, p. 13)....

Perrigo chewses smoking cessation

Perrigo receives ANDA generic drug approvals for over-the-counter nicotine polacrilex gum in 2mg and 4 mg doses Sept. 16. The approvals total six, with regular, mint and orange flavors for each dose. The approvals build on the firm's existing smoking cessation portfolio of nicotine replacement patch products (1"The Tan Sheet" Nov. 15, 1999, p. 13)....

Related Content

Topics

UsernamePublicRestriction

Register

PS090563

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel